Matthew Biegler
Stock Analyst
(1.99)
# 2,175
Out of 4,648 analysts
76
Total ratings
31.67%
Success rate
-4.09%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Maintains: Outperform | $50 → $40 | $27.25 | +46.79% | 3 | Oct 31, 2024 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $53 | $30.00 | +76.70% | 5 | Oct 29, 2024 | |
| TYRA Tyra Biosciences | Maintains: Outperform | $25 → $33 | $16.56 | +99.34% | 6 | Sep 19, 2024 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Outperform | $20 | $3.92 | +410.20% | 7 | Sep 16, 2024 | |
| RLAY Relay Therapeutics | Downgrades: Perform | n/a | $5.93 | - | 6 | Sep 10, 2024 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $17 → $15 | $9.42 | +59.32% | 4 | Aug 13, 2024 | |
| ALLO Allogene Therapeutics | Assumes: Outperform | $13 → $11 | $2.98 | +268.97% | 1 | Aug 8, 2024 | |
| OLMA Olema Pharmaceuticals | Reiterates: Outperform | $30 | $12.03 | +149.38% | 4 | Aug 7, 2024 | |
| BPMC Blueprint Medicines | Maintains: Outperform | $114 → $125 | $91.82 | +36.14% | 5 | Jul 8, 2024 | |
| RNAC Cartesian Therapeutics | Downgrades: Peer Perform | n/a | $19.62 | - | 4 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $3.34 | +319.16% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 → $10 | $0.81 | +1,140.39% | 6 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $4.71 | - | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $2.56 | - | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $14.94 | - | 2 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $15 | $0.38 | +3,847.37% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $7.89 | +216.86% | 1 | Jun 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.34 | - | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.41 | - | 2 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $520 → $360 | $5.39 | +6,582.75% | 1 | Nov 30, 2022 |
Arvinas
Oct 31, 2024
Maintains: Outperform
Price Target: $50 → $40
Current: $27.25
Upside: +46.79%
IDEAYA Biosciences
Oct 29, 2024
Reiterates: Outperform
Price Target: $53
Current: $30.00
Upside: +76.70%
Tyra Biosciences
Sep 19, 2024
Maintains: Outperform
Price Target: $25 → $33
Current: $16.56
Upside: +99.34%
Zentalis Pharmaceuticals
Sep 16, 2024
Reiterates: Outperform
Price Target: $20
Current: $3.92
Upside: +410.20%
Relay Therapeutics
Sep 10, 2024
Downgrades: Perform
Price Target: n/a
Current: $5.93
Upside: -
ORIC Pharmaceuticals
Aug 13, 2024
Maintains: Outperform
Price Target: $17 → $15
Current: $9.42
Upside: +59.32%
Allogene Therapeutics
Aug 8, 2024
Assumes: Outperform
Price Target: $13 → $11
Current: $2.98
Upside: +268.97%
Olema Pharmaceuticals
Aug 7, 2024
Reiterates: Outperform
Price Target: $30
Current: $12.03
Upside: +149.38%
Blueprint Medicines
Jul 8, 2024
Maintains: Outperform
Price Target: $114 → $125
Current: $91.82
Upside: +36.14%
Cartesian Therapeutics
Jul 2, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $19.62
Upside: -
May 14, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $3.34
Upside: +319.16%
May 13, 2024
Reiterates: Outperform
Price Target: $15 → $10
Current: $0.81
Upside: +1,140.39%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $4.71
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $2.56
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $14.94
Upside: -
Aug 11, 2023
Maintains: Outperform
Price Target: $50 → $15
Current: $0.38
Upside: +3,847.37%
Jun 2, 2023
Initiates: Outperform
Price Target: $25
Current: $7.89
Upside: +216.86%
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $3.34
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $1.41
Upside: -
Nov 30, 2022
Maintains: Outperform
Price Target: $520 → $360
Current: $5.39
Upside: +6,582.75%